Annual Hawaii Dermatology Seminar


March 16 - 20, 2021


CME/CE Credit

We are in the process of putting together the SDEF's 45th Annual Hawaii Dermatology Seminar program.

Please SIGN UP for email updates to keep informed of program developments for our upcoming conference as they become available.




2020 Information:



At the conclusion of this live conference, participants should be better able to:

  • Apply evidence-based pharmacologic and nonpharmacologic strategies to the management of patients with acne.
  • Review current scientific findings that demonstrate the underlying pathophysiology of, and the treatment targets for, acne vulgaris.
  • Discuss the factors that increase a patient’s risk for developing actinic keratosis.
  • Design a treatment strategy for actinic keratosis that improves outcomes while minimizing the potential risk of complications.
  • Discuss the benefits and risks of current agents and techniques commonly used in aesthetic and procedural dermatology.
  • Select filler agents suitable for use in treating different facial areas.
  • Design a nonsurgical treatment strategy, including potential use of neuromodulators, to address patient concerns about facial aging.
  • Develop a treatment approach for atopic dermatitis that achieves the goal of clear or almost clear skin.
  • Review safety and efficacy data on therapies that target the inflammatory component of atopic dermatitis.
  • Compare and contrast the symptomatology of atopic dermatitis and the differences in the approach to treatment for adults vs pediatric patients.
  • Recognize the role of dermoscopy in diagnosis and management of various skin lesions.
  • List signs, symptoms, and diagnostic indicators of hidradenitis supparitiva severity levels and describe initial steps for treatment.
  • Selectively treat patients based on an accurate diagnosis or refer patients for specialty care.
  • Identify the conditions under which patients with hidradenitis supparitiva would be eligible for treatment with biologic therapies.
  • Describe recent scientific findings that explicate the inflammatory basis of psoriasis.
  • Discuss current clinical guidelines for optimal diagnosis and treatment of psoriasis.
  • Review safety and efficacy data on new and emerging therapies for psoriasis.
  • Implement a strategy for stepwise management of psoriasis with topical and biologic agents, including the use of treat-to-target goals.
  • Apply current strategies for assessing and treating dermatologic conditions in pediatric patients, including acne, infections, birthmarks, hair disorders, and skin tumors.
  • Identify when epicutaneous patch testing is appropriate in pediatric patients.
  • Discuss safety and efficacy data on current and emerging therapies for rosacea.
  • Define appropriate goals and strategies for the optimal management of patients with rosacea.
  • Distinguish between benign nevi and suspicious neoplasms.
  • Discuss available treatment strategies for melanoma at various stages of its progression.
  • Identify high-risk tumor characteristics and indications for Mohs surgery and the impact of patient characteristics and expectations on the results of the procedure.
  • Recognize the need for increased vigilance for the development of skin cancer in immunocompromised patients.
  • Explain available methods for assessing and monitoring Spitz nevi.
  • Describe available nonsurgical options for managing superficial nonmelanoma lesions.
  • Define the underlying processes that lead to Merkel cell carcinoma, how recurrences can be diagnosed early, and resources for management.
  • Discuss NCCN guidelines on melanoma surveillance, diagnostic tests and recurrence risk calculators.
  • Describe techniques for managing keloids that offer the greatest benefits with minimal risk of scarring.
  • Diagnose, and develop treatment strategies for hypopigmentation disorders.
  • Discuss the latest data on the prevalence, severity, and impact of primary axillary hyperhidrosis and other common forms of hyperhidrosis.
  • Outline strategies for diagnosing primary axillary hyperhidrosis and other forms of hyperhidrosis, including the use of validated instruments to assess the impact of the condition on affected patients.
  • Review the evidence regarding the efficacy and safety profile of various first‐line and subsequent therapies for various types of hyperhidrosis, as well as patient candidacy for the different treatments.




This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and Skin Disease Education Foundation/ Global Academy for Medical Education, LLC. The University of Louisville is accredited by the ACCME to provide continuing education for physicians.

The University of Louisville School of Medicine designates this live activity for a maximum of 32.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The self-assessment program offered at the 44th Hawaii Dermatology Seminar is approved by the American Board of Dermatology (ABD) for MOC-D self-assessment points. Please be sure to report completion of any self-assessment programs on your MOC-D table located in your ABD profile (

This Live activity, Skin Disease Education Foundation's 44th Hawaii Dermatology Seminar, with a beginning date of 02/16/2020, has been reviewed and is acceptable for up to  32.5 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Postgraduate Institute for Medicine designates this continuing education activity for 32.5 contact hours (3.25 CEUs) of the Accreditation Council for Pharmacy Education. Type of Activity Application Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. Universal Activity Number(s)- to be listed on the handout.

The maximum number of hours awarded for this Continuing Nursing Education activity is 32.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.


As a provider accredited by the ACCME, it is the policy of the University of Louisville Office of Continuing Medical Education & Professional Development to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers will be disclosed to participants at the beginning of the activity.


Follow Us